ATE420102T1 - An der metastase beteiligter faktor und verwendungen dafür - Google Patents

An der metastase beteiligter faktor und verwendungen dafür

Info

Publication number
ATE420102T1
ATE420102T1 AT03769423T AT03769423T ATE420102T1 AT E420102 T1 ATE420102 T1 AT E420102T1 AT 03769423 T AT03769423 T AT 03769423T AT 03769423 T AT03769423 T AT 03769423T AT E420102 T1 ATE420102 T1 AT E420102T1
Authority
AT
Austria
Prior art keywords
metastasis
polypeptide
amino acid
extracellular matrix
sequence according
Prior art date
Application number
AT03769423T
Other languages
English (en)
Inventor
Anke Klippel-Giese
Joerg Kaufmann
Rolf Schwarzer
Original Assignee
Silence Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silence Therapeutics Ag filed Critical Silence Therapeutics Ag
Application granted granted Critical
Publication of ATE420102T1 publication Critical patent/ATE420102T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03769423T 2002-10-18 2003-10-20 An der metastase beteiligter faktor und verwendungen dafür ATE420102T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02023384 2002-10-18

Publications (1)

Publication Number Publication Date
ATE420102T1 true ATE420102T1 (de) 2009-01-15

Family

ID=32103889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03769423T ATE420102T1 (de) 2002-10-18 2003-10-20 An der metastase beteiligter faktor und verwendungen dafür

Country Status (19)

Country Link
US (2) US20060240022A1 (de)
EP (2) EP1551868B1 (de)
JP (2) JP4820092B2 (de)
KR (1) KR101154130B1 (de)
CN (1) CN100564524C (de)
AT (1) ATE420102T1 (de)
AU (2) AU2003278112A1 (de)
BR (1) BR0315411A (de)
CA (1) CA2501333A1 (de)
CY (1) CY1110313T1 (de)
DE (1) DE60325754D1 (de)
DK (1) DK1551868T3 (de)
ES (1) ES2319891T3 (de)
IL (1) IL167801A (de)
MX (1) MXPA05004134A (de)
PT (1) PT1551868E (de)
SI (1) SI1551868T1 (de)
WO (1) WO2004035615A2 (de)
ZA (1) ZA200502483B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405292B2 (en) 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
EP2258847B2 (de) 2002-08-05 2020-07-01 Silence Therapeutics GmbH Weitere neue formen von interferierende rns moleküle
US20060240022A1 (en) * 2002-10-18 2006-10-26 Atugen Ag Factor involved in metastasis and uses thereof
EP1791568B1 (de) 2004-08-16 2012-08-15 Quark Pharmaceuticals, Inc. Therapeutische verwendungen von rtp801-hemmern
CN100357323C (zh) * 2006-01-05 2007-12-26 清华大学 一种细胞迁移相关蛋白及其编码基因与应用
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
WO2008054534A2 (en) * 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
JP2010518880A (ja) 2007-02-26 2010-06-03 クアーク・ファーマスーティカルス、インコーポレイテッド Rtp801のインヒビター及びその疾患の治療における使用
WO2010021718A1 (en) 2008-08-19 2010-02-25 Nektar Therapeutics Complexes of small-interfering nucleic acids
WO2011035065A1 (en) 2009-09-17 2011-03-24 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US9932578B2 (en) 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
AU743469C (en) 1996-08-30 2004-02-12 Rolf Bald Mirror-symmetrical selection and evolution of nucleic acids
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
JP2003525017A (ja) 1998-04-20 2003-08-26 リボザイム・ファーマシューティカルズ・インコーポレーテッド 遺伝子発現を調節しうる新規な化学組成を有する核酸分子
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
EP1185543A4 (de) * 1999-06-11 2003-09-03 Human Genome Sciences Inc 50 human-sekretierte proteine
US6133032A (en) * 1999-09-09 2000-10-17 Isis Pharmaceutical Inc. Antisense modulation of PI3 kinase p110 beta expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
US6673545B2 (en) * 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
WO2002046465A2 (en) * 2000-12-08 2002-06-13 Oxford Biomedica (Uk) Limited Method for identification of genes involved in specific diseases
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
AU2003265556A1 (en) * 2002-08-20 2004-03-11 Millenium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US20060240022A1 (en) * 2002-10-18 2006-10-26 Atugen Ag Factor involved in metastasis and uses thereof
EP1791568B1 (de) * 2004-08-16 2012-08-15 Quark Pharmaceuticals, Inc. Therapeutische verwendungen von rtp801-hemmern

Also Published As

Publication number Publication date
ES2319891T3 (es) 2009-05-14
DE60325754D1 (de) 2009-02-26
MXPA05004134A (es) 2005-10-05
CN1705746A (zh) 2005-12-07
CN100564524C (zh) 2009-12-02
BR0315411A (pt) 2005-08-16
WO2004035615A2 (en) 2004-04-29
DK1551868T3 (da) 2009-04-20
AU2010246370A1 (en) 2010-12-16
US20100285038A1 (en) 2010-11-11
JP4820092B2 (ja) 2011-11-24
AU2003278112A1 (en) 2004-05-04
PT1551868E (pt) 2009-04-06
EP1551868B1 (de) 2009-01-07
CY1110313T1 (el) 2015-01-14
EP1551868A2 (de) 2005-07-13
US20060240022A1 (en) 2006-10-26
SI1551868T1 (sl) 2009-06-30
EP2072619A1 (de) 2009-06-24
ZA200502483B (en) 2005-11-30
JP2011125339A (ja) 2011-06-30
KR101154130B1 (ko) 2012-06-12
JP2006520183A (ja) 2006-09-07
IL167801A (en) 2012-10-31
CA2501333A1 (en) 2004-04-29
WO2004035615A3 (en) 2004-06-03
KR20050056244A (ko) 2005-06-14

Similar Documents

Publication Publication Date Title
CY1110313T1 (el) Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του
Joester et al. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system
Doliana et al. EMILIN, a component of the elastic fiber and a new member of the C1q/tumor necrosis factor superfamily of proteins
Yonemura et al. Protein composition of silk filaments spun under water by caddisfly larvae
Katoh et al. Identification and characterization of human HES2, HES3, and HES5 genes in silico
FI882456A0 (fi) Human proapolipoprotein a-i expression.
ATE528398T1 (de) Transkriptionsfaktor-gen osnacx aus reis und verwendung davon zur verbesserung der toleranz von pflanzen gegenüber trockenheit und salz
AR039003A1 (es) Composiciones y metodos para alterar el contenido de tocotrienoles
DE69926729D1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
DK0624641T3 (da) Termostabil nukleinsyrepolymerase
DE60039055D1 (de) Mittel und methoden zur beeinflussung pflanzlicher blüheigenschaften
ATE526399T1 (de) Neue biologische einheiten und deren verwendung
CY1107335T1 (el) ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17
ATE121457T1 (de) Für das menschliche angiotension-umformungsenzym (ace) kodierende nukleinsäure und ihre anwendungen, insbesondere zur in-vitro-diagnose von bluthochdruck.
ATE453609T1 (de) Herstellung von 1,4-butandiol und/oder 2-methyl 1,3-propandiol
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
WO2007120166A2 (en) Miniaturized in vitro protein expression array
ATE431361T1 (de) Verwendung vom transportergen oatp-c zur screening von testsubstanzen
ATE362486T1 (de) Menschliche, für neurogenin 3 kodierende nukleotidsequenzen
ATE417066T1 (de) Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
RU93031156A (ru) Способ получения плазмид, кодирующих химерный белок с последовательностью соматостатина, штамм бактерий escherichia coli - продуцент этого белка, белок, полученный в этом штамме, содержащий фрагмент ацетилтрансферазы, спейсер и иммуногенный соматостатин
ATE474051T1 (de) Bakterien mit erhöhter proteinsekretion, nukleotidsequenzen codierend fur ein seca protein mit erhöhter proteinsekretion sowie verfahren zur produktion von proteinen
FI880986A0 (fi) Tendamistatderivat.
BR9914130A (pt) Promotores de plantas e terminadores de plantas
BR0316520A (pt) ácidos nucleicos isolados e proteìnas associadas à regulação do metabolismo de lipìdios e açúcar

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1551868

Country of ref document: EP